A number of other analysts also recently issued reports on ALDR. Zacks Investment Research downgraded Alder Biopharmaceuticals from a buy rating to a hold rating in a research note on Tuesday, May 7th. Mizuho reaffirmed a hold rating and issued a $15.00 target price on shares of Alder Biopharmaceuticals in a research note on Friday, May 3rd. Cowen set a $18.00 target price on Alder Biopharmaceuticals and gave the stock a buy rating in a research note on Friday, May 3rd. Finally, Canaccord Genuity cut their target price on Alder Biopharmaceuticals from $21.00 to $20.00 and set a buy rating for the company in a research note on Thursday, March 14th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and eight have issued a buy rating to the company. Alder Biopharmaceuticals has an average rating of Hold and an average price target of $20.64.
Shares of ALDR opened at $11.35 on Thursday. Alder Biopharmaceuticals has a 52-week low of $9.44 and a 52-week high of $20.87. The firm has a market capitalization of $976.16 million, a price-to-earnings ratio of -2.33 and a beta of 2.74. The company has a debt-to-equity ratio of 1.21, a current ratio of 8.34 and a quick ratio of 14.87.
In other news, EVP James B. Bucher sold 1,897 shares of the stock in a transaction on Thursday, April 25th. The stock was sold at an average price of $13.85, for a total transaction of $26,273.45. Following the completion of the transaction, the executive vice president now directly owns 11,706 shares in the company, valued at approximately $162,128.10. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 17.40% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in ALDR. Principal Financial Group Inc. acquired a new stake in Alder Biopharmaceuticals during the first quarter worth about $146,000. Swiss National Bank boosted its position in shares of Alder Biopharmaceuticals by 3.2% in the first quarter. Swiss National Bank now owns 113,142 shares of the biopharmaceutical company’s stock worth $1,544,000 after buying an additional 3,500 shares during the period. DekaBank Deutsche Girozentrale boosted its position in shares of Alder Biopharmaceuticals by 22.2% in the first quarter. DekaBank Deutsche Girozentrale now owns 24,200 shares of the biopharmaceutical company’s stock worth $432,000 after buying an additional 4,400 shares during the period. Fosun International Ltd boosted its position in shares of Alder Biopharmaceuticals by 26.5% in the first quarter. Fosun International Ltd now owns 233,858 shares of the biopharmaceutical company’s stock worth $3,113,000 after buying an additional 49,045 shares during the period. Finally, Parametric Portfolio Associates LLC boosted its position in shares of Alder Biopharmaceuticals by 3.1% in the first quarter. Parametric Portfolio Associates LLC now owns 61,559 shares of the biopharmaceutical company’s stock worth $840,000 after buying an additional 1,842 shares during the period.
Alder Biopharmaceuticals Company Profile
Alder BioPharmaceuticals, Inc operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine in the United States, Australia, and Ireland. The company's lead product candidate is eptinezumab, a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide, which is in the late-stage clinical development for the prevention of migraine.
Featured Story: Quiet Period
Receive News & Ratings for Alder Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.